<DOC>
	<DOC>NCT01997372</DOC>
	<brief_summary>Severe acquired aplastic anaemia (SAA) is a life-threatening disease characterized by pancytopenia and hypoplastic bone marrow. Immunosuppressive treatment with antithymocyte globulin (ATG)and cyclosporine remain the standard regimen with response rates of 70% or more and excellent overall survival. However ,there are no clinical trials to illustrate the response and complete remission rate with different doses of ATG.And there are no data reported on children with SAA so far.</brief_summary>
	<brief_title>Different Doses of Anti-thymocyte Globin to Treat Child Severe Aplastic Anemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia, Aplastic</mesh_term>
	<criteria>clinical diagnosis of childhood acquired severe aplastic anemia(SAA) clinical diagnosis of no childhood acquired severe aplastic anemia(SAA)</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>ATG</keyword>
	<keyword>SAA</keyword>
	<keyword>immunosuppressive treatment</keyword>
	<keyword>cyclosporine</keyword>
</DOC>